Introducing 2nd generation
Current Immunotherapy for fighting cancer is using only one arm of the immune system - adaptive Immunity.
Our oral medicine stimulates innate immunity, adding both arms of the immune system in the fight. It is expected to treat many types of cancers - prolonging life for far more patients.
We are pleased to report the closing of the Company’s Series Seed round of $2M.
Immunity has two major arms and current therapies invoke only one of them.
CAR-T and Checkpoint Inhibitors
The best, current immune-oncology therapies are in adaptive immunity. They modify T-cells (CAR-T) or block adaptive immunity suppressive proteins (PD-1, PD-L1 – so called checkpoints) through checkpoint inhibitors. These therapies have made great strides, but resistance is increasing and many tumors do not respond to these therapies.
Our Target: ENPP1
Cancer secretes immune suppressive proteins that provide it stealth-like capability against the human immune system – the half that launches defensive T-cells and antibodies (adaptive immunity) we are treating today.
This is why checkpoint inhibitors have been a revolutionary approach to fighting cancer. However, cancer develops resistance to checkpoint inhibitors, so using them alone is like fighting with one hand behind your back.
The second half of the immune system is the innate immunity built into every cell – the surveilling for cancer and foreign DNA/RNA which alerts adaptive immunity to the site of the problem and the first responder immunity that inflames the cell so adaptive immunity knows where to attack and so interferon and inflammation can fight the cancer. But cancer secretes another protein — called ENPP1 — that blocks innate immunity and stops this important process.
Defeating ENPP1 is our goal. And it’s a revolutionary new approach that enables the full, two-fisted immune system to stop cancer. This is our approach to taking immune oncology to the next revolution for patients.
Get in touch and we’ll get back to you as soon as we can. Thanks.